Found: 5
Select item for more details and to access through your institution.
Cannabinoid CB receptor activation, pharmacological blockade, or genetic ablation affects the function of the muscarinic auto- and heteroreceptor.
- Published in:
- Naunyn-Schmiedeberg's Archives of Pharmacology, 2012, v. 385, n. 4, p. 385, doi. 10.1007/s00210-011-0717-8
- By:
- Publication type:
- Article
Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors.
- Published in:
- Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, v. 372, n. 5, p. 354, doi. 10.1007/s00210-006-0033-x
- By:
- Publication type:
- Article
Lack of CB1 receptors increases noradrenaline release in vas deferens without affecting atrial noradrenaline release or cortical acetylcholine release.
- Published in:
- 2003
- By:
- Publication type:
- journal article
Lack of CB[sub1] receptors increase nonadrenaline release in vas deferens without affecting atrial noradrenaline release or cortical acetycholine release.
- Published in:
- British Journal of Pharmacology, 2003, v. 140, n. 2, p. 323, doi. 10.1038/sj.bjp.0705449
- By:
- Publication type:
- Article
Cannabinoid CB[sub1] receptor-mediated inhibition of hippocampal acetylcholine release is preserved in aged mice.
- Published in:
- British Journal of Pharmacology, 2003, v. 138, n. 8, p. 1425, doi. 10.1038/sj.bjp.0705194
- By:
- Publication type:
- Article